0001209191-20-013620.txt : 20200227
0001209191-20-013620.hdr.sgml : 20200227
20200227210009
ACCESSION NUMBER: 0001209191-20-013620
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190225
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doyle Noah
CENTRAL INDEX KEY: 0001631673
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37428
FILM NUMBER: 20665250
MAIL ADDRESS:
STREET 1: C/O RITTER PHARMACEUTICALS INC.
STREET 2: 1801 CENTURY PARK EAST, SUITE 1820
CITY: LOS ANGELES
STATE: CA
ZIP: 90096
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RITTER PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001460702
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263474527
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1880 CENTURY PARK EAST, SUITE 1000
CITY: LOS ANGELES
STATE: CA
ZIP: 90067
BUSINESS PHONE: 310-203-1000
MAIL ADDRESS:
STREET 1: 1880 CENTURY PARK EAST, SUITE 1000
CITY: LOS ANGELES
STATE: CA
ZIP: 90067
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-25
0
0001460702
RITTER PHARMACEUTICALS INC
RTTR
0001631673
Doyle Noah
RITTER PHARMACEUTICALS, INC.
1880 CENTURY PARK EAST, SUITE 1000
LOS ANGELES
CA
90067
1
0
0
0
Common Stock
2020-02-25
4
M
0
500000
0.15
A
1204780
I
By Javelin Partners, L.P.
Common Stock
32275
I
By Javelin Venture Partners I SPV I, LLC
Common Stock
2272
D
Warrants (right to buy)
0.15
2020-02-25
4
M
0
500000
0.00
D
2017-10-03
2022-10-03
Common Stock
500000
0
I
By Javelin Partners, L.P.
On March 23, 2018, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock (the "Stock Split"). All share numbers and warrant exercise prices in this Form 4 reflect the Stock Split.
As the managing director of Javelin Partners, L.P., the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.
As the managing director of Javelin Venture Partners I SPV I, LLC, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.
As a result of the Stock Split and dilutive issuances of securities after the issuance of the warrants, the exercise price was adjusted to $0.15 per share.
/s/ Noah Doyle
2020-02-27